Synucleinopathies, including Parkinson’s disease (PD), multiple system atrophy, and Lewy body dementias; preclinical and clinical studies evaluating cellular and molecular neurodegeneration, genetic, and other risk factors
Additional Keywords: Functional neurobiology of genetic risk factors; gut-brain axis; microbiome; neuroimmune; neuroinflammation; mood, cognitive dysfunction; LRRK2; synuclein transmission; deep brain stimulation
Dr. Beth-Anne Sieber is a program director in the Movement Disorders and Neurodegeneration (MDN) cluster, managing a research grant portfolio on Parkinson’s disease (PD) and related disorders, dystonia and essential tremor. Her PD grant portfolio includes neurobiological and pharmacological approaches to understand neuronal loss and alterations in brain circuitry; neuroinflammation and neuroimmune aspects of PD and the role of the gut-brain axis. Dr. Sieber also manages the NINDS Udall Centers of Excellence for PD Research program. Prior to joining the NINDS, Dr. Sieber served as a program director at the National Institute of Mental Health (NIMH), where she managed a grant portfolio in developmental neurobiology and co-chaired related efforts for the NIH Neuroscience Blueprint. She received a bachelor’s degree in biology and psychology from Rutgers University and a Ph.D. in Physiology and Neurobiology from a joint program between Rutgers and the University of Medicine and Dentistry of New Jersey. Her postdoctoral studies at the Karolinska Institute explored the role of receptor tyrosine kinases in development and maintenance of dopamine neurons.